Piper Sandler analyst Do Kim raised the firm’s price target on TCR2 Therapeutics to $10 from $8 and keeps an Overweight rating on the shares. The company’s decision to narrow gavo-cel clinical focus to ovarian cancer and restructure operations is likely "prudent" considering continued uncertainty around capital markets, the analyst tells investors in a research note. Kim adds that the prioritization of certain R&D efforts and workforce reductions should extend TCR2’s cash runway until early 2025.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TCRR:
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TCR² Therapeutics Announces Pipeline Priorities for 2023
- TCR2 Therapeutics announces pipeline priorities for 2023
- TCR2 Therapeutics initiated with a Hold at EF Hutton
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)